Here's how the microbiome companies they're betting on plan to succeed.At-home kits that let patients sample their stool offer an alluring promise: insight into what's going on inside our guts.
If the data from the microbiome can be turned into a useful health product, entrepreneurs and investors believe they could be onto the next big wellness trend, similar to the way genetic insights have been turned into a range of hot consumer products by the likes of 23andMe andBut testing poop isn't quite as simple as spitting in a tube for a genetic test.
Kimon Angelides previously founded Livongo, the first digital health startup to go public in three years.A serial entrepreneur with a PhD in biochemistry, Angelides previously helped start Livongo, a company that uses a suite of digital tools to help people with diabetes manage their condition. This summer, Livongo became thein three years. It raised more than $350 million in its IPO, and has a market value of about $1.8 billion.
"Here we can actually help and use digital health therapeutics for what they were designed for," Angelides, who launched Vivante in 2016, told Business Insider.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Herkunft: BusinessInsider - 🏆 729. / 51 Weiterlesen »
Herkunft: BusinessInsider - 🏆 729. / 51 Weiterlesen »
Herkunft: BusinessInsider - 🏆 729. / 51 Weiterlesen »
Herkunft: BusinessInsider - 🏆 729. / 51 Weiterlesen »
Herkunft: BusinessInsider - 🏆 729. / 51 Weiterlesen »
Herkunft: BusinessInsider - 🏆 729. / 51 Weiterlesen »